Expressed sequence tags and encoded human proteins |
| The present invention relates to purified, isolated, or enriched 5' ESTs which include sequences ... |
|
C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| The invention claimed is: 1. An isolated PC-LECTIN protein comprising the amino acid sequence of SEQ... |
|
Antibodies for use in determining hemoglobin A.sub.1c |
| It is accordingly an object of the present invention to provide a comparatively simple, inexpensive,... |
|
Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives |
| OF THE INVENTION A hapten of the invention is substantially optically pure, and is particularly ... |
|
Immunogens and the use thereof for obtaining antibodies against HBA.sub.1C |
| What is claimed is: 1. Composition of matter consisting essentially of polyclonal antibodies which ... |
|
Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| The present invention overcomes the above mentioned drawbacks and provides methods for treating ... |
|
Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay |
| OF THE INVENTION The present invention is directed to methods for developing and utilizing ... |
|
Stimulation of chemotaxis by chemotactic peptides |
| Accordingly, it is an object of this invention to provide a synthetic material having chemotactic ... |
|
Biological material pre-fixation treatment |
| OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic ... |
|
|
Method for generating and identifying antibodies directed against a B7
| Details |
Inventors: Linsley, Peter S.; Ledbetter, Jeffrey A.; Damle, Nitin K.; Brady, William;
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Primary Examiner: Gambel; Phillip
Assistant Examiner:
Attorney, Agent or Firm: Mandel and Adriano
The invention provides a method for generating and identifying antibodies directed against a B7 antigen having SEQ ID NO. 8 or a fragment of SEQ ID NO. 8, which antibodies inhibit B cells from binding CD28, comprising immunizing an animal with the B7 antigen so as to produce the antibodies; and screening the antibodies for antibodies that bind B7 and inhibit CD28 binding to B cells. |
|
DETAILED DESCRIPTION Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 receptor. The B7 antigen, or its fragments or derivatives are reacted with CD28 positive T cells to regulate T cell interactions with other cells. Alternatively, the CD28 receptor, its fragments or derivatives are reacted with B7 antigen to regulate interactions of B7 positive cells with T cells. In addition, antibodies or other molecules reactive with the B7 antigen or CD28 receptor may be used to inhibit interaction of cells associated with these molecules, thereby regulating T cell responses. A preferred embodiment of the invention provides a method for regulating CD28 specific T cell interactions by reacting CD28 positive T cells with B7 antigen, or its fragments or derivatives, so as to block the functional interaction of T cells with other cells. The method for reacting a ligand for CD28 with T cells may additionally include the use of anti-CD monoclonal antibodies such as anti-CD2 and/or anti-CD3 monoclonal antibody. In an alternative embodiment, the invention provides a method for regulating immune responses by contacting CD28 positive T cells with fragments containing at least a portion of the DNA sequence encoding the amino acid sequence corresponding to the extracellular domain of B7 antigen. In addition, derivatives of B7 antigen may be used to regulate immune responses, wherein the derivatives are fusion protein constructs including at least a portion of the extracellular domain of B7 antigen and another protein, such as human immunoglobulin C gamma 1, that alters the solubility, binding affinity and/or valency of B7 antigen. For example, in a preferred embodiment, DNA encoding amino acid residues from about position 1 to about position 215 of the sequence corresponding to the extracellular domain of B7 antigen is joined to DNA encoding amino acid residues of the sequences corresponding to the hinge, CH2 and CH3 regions of human Ig C. gamma. 1 to form a DNA fusion product which encodes B7Ig fusion protein
|
| Related patents |
|
|
Polypeptide that interacts with heat shock proteins
Described herein are the isolation and characterization of a polypeptide, particularly a tetratricopeptide repeat (TPR)-containing polypeptide that is an interactive ...
|
|
|
1,2-Biguanides
What is claimed is: 1. A substituted biguanide of the formula ##EQU8## wherein R.sub.1 is alkyl of 1-8 carbon atoms, R'.sub.1 is hydrogen or alkyl of 1-8 carbon atoms ...
|
|
|
Biguanide salts
OF THE INVENTION The invention relates to biguanide salts. In another aspect, the invention relates to pharmaceutical preparations which contain the aforementioned ...
|
|
|
Inhibitors of dipeptidyl-aminopeptidase type IV
What is claimed is: 1. A method for treating transplant rejection in a patient comprising administering to said patient an inhibitor of DP-IV, having the structure: ##STR...
|
|
|
Process for preparing anti-obesity protein
OF THE INVENTION For purposes of the present invention, as disclosed and claimed herein, the following terms and abbreviations are as defined below. dDAP--a ...
|
|
|
Use of GLP-1 or analogs to abolish catabolic changes after surgery
The present invention therefore presents for the first time a method of attenuating post-surgical catabolic changes and insulin resistance, comprising, administering to ...
|
|
|
Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury
OF THE INVENTION The present invention provides a method for effective treatment of spinal cord injury. The method involves administering an effective amount of ...
|
|
|
Leptospira rare outer membrane proteins
The present invention presents two novel leptospiral membrane proteins: LipL1 and LipL2. In particular, these proteins are lipoproteins which are associated with ...
|
|
|
Interleukin-1 beta converting enzyme like apoptotic protease-6
Toward these ends, and others, it is an object of the present invention to provide polypeptides, inter alia, that have been identified as novel ICE LAP-6 by homology ...
|
|
|
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
What is claimed is: 1. A therapeutic composition comprising at least one angiogenesis inhibiting agent, which is an .alpha..sub.v.beta..sub.3 antagonist; and at least ...
|
|
|